Psychotherapeutic Drugs:The World Market for Antidepressants, Antipsychotics, Antianxiety Drugs, Smoking Cessation and Addiction Treatments

Table of Contents

Chapter One: Executive Summary

• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting Market
• Competitive Summary
• Company Profiles

Chapter Two: Introduction

• Conditions
  • Depressive Disorders
  • Depression
  • Seasonal Affective Disorder
  • Psychotic Disorders
  • Bipolar Disorder
  • Schizophrenia
  • Anxiety Disorders
  • Attention Deficit Disorders
  • Eating Disorders
  • Addiction Disorders
• Condition Statistics
  • Depression
  • Dysthymic Disorder
  • Seasonal Affective Disorder (SAD)
  • Bipolar Disorder
  • Psychomotor Agitation
  • Tourette Syndrome
  • Schizophrenia
  • Generalized Anxiety Disorder
  • Social Anxiety Disorder
  • Obsessive Compulsive Disorder
  • Panic Disorder
  • Post Traumatic Stress Disorder
  • Phobias
  • Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD)
  • Nicotine, Alcohol, and Drug Addiction
  • Bulimia/Anorexia
  • Premenstrual Dysphoric Disorder
• History and Growth of the Psychotherapeutic Drug Market
• Industry Structure and Product Segments

Chapter Three: Antidepressants

• Overview
• Description of Depression
  • Epidemiology of Depression
  • Economic Impact of Depression
• Description of Products
  • Monoamine Oxidase Inhibitors
    • Nardil
    • Parnate
  • Selective Serotonin Reuptake Inhibitors
    • Prozac/Sarafem
    • Paxil/Seroxat and Paxil CR
    • Zoloft
    • Celexa
    • Lexapro
  • Serotonin and Norepinephrine Reuptake Inhibitors
    • Effexor and Effexor XR
    • Cymbalta
  • Aminoketones
    • Wellbutrin and Wellbutrin XL and Wellbutrin SR
  • Phenylpiperazines
    • Serzone
    • Desyrel
  • Tetracyclics and Miscellaneous
    • Remeron
    • Symbyax
    • Tolvon
    • EMSAM
• Products in Research and Development
  • Desvenlafaxine succinate
  • Gepirone ER
  • Vilazodone
  • Seroquel SR
  • Saredutant (SR 48968)
  • SR 58611
  • DOV 216,303
  • Corlux
  • Valdoxan
• Market Size and Growth
  • Total World Market
  • Markets by Geographical Segments
    • U.S. Market
    • European Union Market
    • Japan Market
    • ROW Market
  • Market Data by Indication
• Competitive Analysis

Chapter Four: Antipsychotics and Antimanics

• Overview
  • Description of Conditions
    • Schizophrenia
    • Bipolar Disorder
    • Tourette' s Syndrome
  • Epidemiology
  • Economic Impact
• Description of Products
  • Phenothiazines
    • Compazine, Serentil, Stelazine, Thorazine
    • Geodon
  • Thienobenzodiazepines
    • Zyprexa
  • Benzisoxazole Derivatives
    • Risperdal, Risperdal Consta
  • Dibenzodiazepine and Dibenzothiazepine Derivatives
    • Clozaril
    • Seroquel
  • Dopamine Partial Agonist
    • Abilify
  • Lithium
    • Lithobid, Eskalith
  • Miscellaneous
    • Symbyax
    • Lamictal
  • Research and Development
    • Paliperidone, Paliperidone ER, Paliperidone Palmitate IM
    • Asenapine
    • Bifeprunox
    • Lamictal
    • Iloperidone (Zomaril)
    • LIC 477D
    • Seroquel SR
  • Market Size and Growth
    • Total World Market
    • Markets by Geographical Segments
      • U.S. Market
      • European Union Market
      • Japan Market
      • ROW Market
    • Market Data by Indication
  • Competitive Analysis

Chapter Five: Antianxiety Drugs

• Overview
  • Description of Conditions
  • Economic Impact
• Description of Products
  • Benzodiazipines
    • Xanax
    • Ativan
    • Klonopin
    • Valium
    • Versed
  • Miscellaneous Antianxiety Agents
    • BuSpar
    • Lexotan
    • Prozac/Sarafem
    • Paxil/Seroxat and Paxil CR
    • Zoloft
    • Effexor and Effexor XR
  • Research and Development
    • Cipralex
    • Cymbalta
    • Lyrica
    • Desvenlafaxine succinate
    • DOV 216,303
    • PDX 00023
    • Gepirone ER
    • Saredutant (SR 48968)
    • SR 58611
    • Valdoxan
  • Market Size and Growth
    • Total World Market
    • Markets by Geographical Segments
      • U.S. Market
      • European Union Market
      • Japan Market
      • ROW Market
    • Market Data by Indication
  • Competitive Analysis

Chapter SIX: CNS Stimulants and Nonstimulant Attention Deficit Hyperactive Disorder Treatments

• Overview
  • Description of Conditions
  • Economic Impact
• Description of Products
  • Amphetamines
    • Ritalin
    • Focalin and Focalin XR
    • Daytrana
  • Selective Norepinephrine Reuptake Inhibitors
    • Strattera
  • Central Nervous System Stimulants
    • Concerta
    • Metadate CD
  • Sympathomimetic Amines
    • Adderall and Adderall XR
  • Research and Development
    • NRP104/LDX
    • Guanfacine ER (SPD-503)
    • SPD-465
  • Market Size and Growth
    • Total World Market
    • Markets by Geographical Segments
      • U.S. Market
      • European Union Market
      • Japan Market
      • ROW Market
    • Competitive Analysis

Chapter Seven: Other Psychotherapeutic Drugs

• Overview
  • Description of Conditions
    • Eating Disorders - Anorexia and Bulimia
    • Substance Abuse - Alcohol, Narcotic, Nicotine
    • Premenstrual Dysphoric Disorder
  • Economic Impact
• Description of Products
  • Smoking Cessation
    • Chantix/Champix
    • Zyban
    • Accomplia
    • Nicotrol
  • Alcohol and Opiate Dependence and Related
    • Subutex
    • Campral
    • Methodone
    • ReVia/Naltrex
    • Antabuse
    • Narcan
    • Vivitrol
    • Depade
  • Bulimia/Anorexia
    • Prozac
  • Premenstrual Dysophoric Syndrome
    • YAZ
    • SSRIs
• Research and Development
  • Acomplia
  • Lofexidine
  • Naltrexone Depot
  • Lybrel
  • SSR591813
  • Cyt002-NicQb
  • NicVAX
• Market Size and Growth
  • Total World Market
  • Markets by Geographical Segments
    • U.S. Market
    • European Union Market
    • Japan and ROW Market
  • Market Data by Indication
• Competitive Analysis

Chapter Eight: Issues and Trends Affecting the Psychotherapeutic Drug Market

• introduction
  • Patent Expiration Tactics
  • Smoking Cessation and Genetic Testing
  • New Drug Targets
  • ADHD Drugs
  • Caring Across Communities Program
  • Prescription Drug Abuse
  • Drug Advertising and Promotion

Chapter Nine: The Evolving Psychotherapeutic

• Drug Market:
• Market Forecasts
  • Overview
  • Total market Size and Forecast
  • Competitor Analysis

Chapter TeN: Company Profiles

• Introduction
• Competitive Summary
• Astellas Pharma, Inc.
• AstraZeneca Plc
• Biovail Corporation
• Bristol-Myers Squibb
• Eli Lilly & Company
• Forest Laboratories, Inc.
• GlaxoSmithKline Plc
• H. Lundbeck A/S
• Johnson & Johnson
• Otsuka Pharmaceutical Co. Ltd.
• Pfizer, Inc.
• Shire Pharmaceuticals Group Plc
• Wyeth

Appendix

Company Directory

List of Exhibits

Chapter One: Executive Summary

• Table 1-1: Market Summary: Total World Psychotherapeutic Drug Market 2003-2010
• Figure 1-1: Trending in the World Market for Psychotherapeutic Drugs 2003-2010

Chapter TWO: INTRODUCTION

• Table 2-1: Estimated World and U.S. Prevalence of Psychotic Conditions or Disorders
• Figure 2-1: Estimated World Prevalence of Psychotic Conditions or Disorders
• Figure 2-2: Estimated U.S. Prevalence of Psychotic Conditions or Disorders

Chapter THREE: ANTIDEPRESSANTS

• Table 3-1: Estimated World and U.S. Prevalence of Depression
• Figure 3-1: Estimated World and U.S. Prevalence of Depression
• Table 3-2: Recent FDA Antidepressant Approvals, 2003-2006 (Product, Generic Name, Manufacturer/Marketer, Approval Date, Patent Expiration Date)
• Table 3-3: Antidepressants in Research and Development (Product, Developer, Indication, Phase)
• Table 3-4: The World Market for Antidepressant Drugs 2003-2010
• Figure 3-2: Trending in the World Market for Antidepressant Drugs, 2003-2010
• Table 3-5: The World Market for Antidepressant Drugs by Product Classification (SSRIs, S/NRIs, Others) 2003-2010
• Figure 3-3: Trending in the World Market for Antidepressant Drugs by Product Class, 2003-2010
• Figure 3-4: Revenue Distribution by Product Class in the World Market for Antidepressant Drugs, 2003-2010
• Table 3-6: The World Market for Antidepressant Drugs by Geographical Segment (U.S., European Union, Japan, ROW) 2003-2010
• Figure 3-5: Trending in the Regional Markets for Antidepressant 2003-2010
• Table 3-7: Estimated Antidepressant Sales by Indication (Depression and Major Depressive Disorder vs Seasonal Affective Disorder), 2005
• Table 3-8: The World Market for Antidepressant Drugs Revenues and Market Share of Leading Suppliers Esitmated 2005 and Projected 2010
• Figure 3-6: Leading Suppliers' Shares of the World Antidepressant Drug Market 2005
• Figure 3-7: Leading Suppliers' Shares of the World Antidepressant Drug Market 2010
• Table 3-9: Estimated Sales and Market Share of Top Antidepressant Drugs 2005
• Figure 3-8: Leading Products' Shares of the World Antidepressant Drug Market 2005

Chapter FOUR: ANTIPSYCHOTICS AND ANTIMANICS

• Table 4-1: Estimated World and U.S. Prevalence of Psychotic and Manic Disorders
• Figure 4-1: Estimated World and U.S. Prevalence of Psychotic and Manic Disorders
• Table 4-2: Recent FDA Antipsychotic/Antimanic Approvals, 2003-2006 (Product, Generic Name, Manufacturer/Marketer, Approval Date, Patent Expiration Date)
• Table 4-3: Antipsychotics and Antimanics in Research and Development (Product, Developer, Indication, Phase)
• Table 4-4: World Market : Antipsychotic and Antimanic Drugs, 2003-2010
• Figure 4-2: World Market Antipsychotic and Antimanic Drugs, 2003-2010
• Table 4-5:: World Market: Antipsychotic and Antimanic Drugs by Product Classification, 2003-2010
• Figure 4-3: World Market Antipsychotic and Antimanic Drugs by Product Classification Revenues, 2003-2010
• Figure 4-4 World Market: Antipsychotic and Antimanic Drugs by Product Classification and Percent Distribution, 2003-2010
• Figure 4-5 : World Market Antipsychotic and Antimanic Drugs by Product Classification and Percent Market Share, 2005
• Figure 4-6: World Market and Antimanic Drugs by Product Classification and Percent Market Share, 2010
• Table 4-6: World Market Antipsychotic and Antimanic Drug Market by Geographical Segment, 2003-2010 Figure 4-7: World Market Antipsychotic and Antimanic Drug Market by Geographical Segment, 2003-2010
• Figure 4-8 World Market Antipsychotic and Antimanic Drug Market by Geographical Segment Percent Distribution, 2003-2010
• Figure 4-9 World Market Antipsychotic and Antimanic Drug Market by Geographical Segment and Percent Market Share, 2005
• Figure 4-10: World Market Antipsychotic and Antimanic Drug Market by Geographical Segment and Percent Market Share, 2010
• Table 4-7: Estimated Antipsychotic and Antimanic Drug Sales by Indication, 2005
• Figure 4-11 Estimated Antipsychotic and Antimanic Drug Sales by Indication, 2005
• Table 4-8: World Market : Antipsychotic and Antimanic Drug: Leading Suppliers Shares by Market Revenues, Estimated 2005 and Projected 2010
• Figure 4-12: World Market: Antipsychotic and Antimanic Drugs Leading Suppliers Market Share, Estimated 2005
• Table 4-9: Antipsychotic and Antimanic Drug Market, 2003-2010; Top Antipsychotic and Antimanic Drugs by Estimated Sales and Percent of Market, 2005
• Figure 4-13: Antipsychotic and Antimanic Drug Market, 2003-2010 ; Top Antipsychotic and Antimanic Drugs by Estimated Sales and Percent of Market, 2005

Chapter FIVE: ANTIANXIETY DRUGS

• Table 5-1: Estimated World and U.S. Prevalence of Conditions
• Figure 5-1: Estimated World and U.S. Prevalence of Conditions
• Table 5-2: Research and Development: Antianxiety Drugs
• Table 5-3: World Market Antianxiety Drugs, 2003-2010
• Figure 5-2: World Market Antianxiety Drugs, 2003-2010
• Table 5-4: World Market: Drugs by Product Classification, 2003-2010
• Figure 5-3 World Market Antianxiety Drugs by Product Classification Revenues, 2003-2010
• Figure 5-4 World Market Antianxiety Drugs by Product Classification and Percent Distribution, 2003-2010
• Table 5-5: Antianxiety Drugs by Product Classification and Percent Distribution, 2003-2010
• Figure 5-5 Antianxiety Drugs by Product Classification and Percent Market Share, 2005
• Figure 5-6 World Market: Antianxiety Drugs by Product Classification and Percent Market Share, 2010
• Table 5-5: World Market: Antianxiety Drug Market by Geographical Segment, 2003-2010
• Figure 5-7: World Market Antianxiety Drug Market by Geographical Segment, 2003-2010
• Figure 5-8: World Market: Drug Market by Geographical Segment Percent Distribution, 2003-2010
• Figure 5-9: World Market Antianxiety Drug Market by Geographical Segment and Percent Market Share, 2005
• Figure 5-10: Market Drug Market by Geographical Segment and Percent Market Share, 2010
• Table 5-6: Estimated Antianxiety Drug Sales by Indication, 2005
• Figure 5-11: Antianxiety Drug Sales by Indication, 2005
• Table 5-7: World Market: Antianxiety Drugs: Leading Suppliers Shares by Market Revenues, Estimated 2005 and Projected 2010
• Figure 5-12: Market Antianxiety Drugs Leading Suppliers Market Share, Estimated 2005
• Figure 5-13: World Market Antianxiety Drugs: Suppliers Market Share, Projected 2010 Table 5-8: Antianxiety Drug Market, 2003-2010 Top Antianxiety Drugs by Estimated Sales and Percent of Market, 2005
• Figure 5-14: Drug Market, 2003-2010 Top Antianxiety Drugs by Estimated Sales and Percent of Market, 2005

Chapter SIX: CNS STIMULANTS AND NONSTIMULANT ATTENTION DEFICIT HYPERACTIVE DISORDER TREATMENTS

• Table 6-1: Estimated World and U.S. Prevalence of Conditions
• Figure 6-1: Estimated World and U.S. Prevalence of Conditions
• Table 6-2: Recent Stimulant Approvals, 2003-2006
• Table 6-3: Research and Development: Stimulants
• Table 6-4: World Market Stimulants and Non-Stimulants in the ADHD Market, 2003-2010
• Figure 6-2: World Market: Stimulants and Non-Stimulants in the ADHD Market, 2003-2010
• Table 6-5: World Market: Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment, 2003-2010
• Figure 6-3: World Market: Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment, 2003-2010
• Figure 6-4: World Market: Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment Percent Distribution, 2003-2010
• Figure 6-5: World Market : Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment and Percent Market Share, 2005
• Figure 6-6: World Market: Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment and Percent Market Share, 2010
• Table 6-6: World Market: Stimulants and Non-Stimulants in ADHD Treatment Leading Suppliers Shares by Market Revenues,
• Figure 6-7: World Market: Stimulants and Non-Stimulants in ADHD Treatment
• Figure 6-8: World Market: Stimulants and Non-Stimulants in ADHD Treatment
• Table 6-7: Stimulants and Non-Stimulants in the ADHD Market, 2003-2010
• Figure 6-9: Stimulants and Non-Stimulants in the ADHD Market, 2003-2010

Chapter SEVEN: OTHER PSYCHOTHERAPEUTIC DRUGS

• Table 7-1: Estimated World Prevalence of Conditions
• Figure 7-1: Estimated World Prevalence of Conditions
• Table 7-2: Recent Other Psychotherapeutic Drug Approvals
• Table 7-3: and Development: Other Psychotherapeutic Drugs
• Figure 7-2: Research and Development: Other Psychotherapeutic Drugs
• Table 7-4: World Market: Other Psychotherapeutic Drugs, 2003-2010
• Figure 7-2: World Market: Other Psychotherapeutic Drugs, 2003-2010
• Table 7-5: World Market:Other Psychotherapeutic Drugs by Product Classification, 2003-2010
• Figure 7-3: Other Psychotherapeutic Drugs by Product Classification Revenues,
• Figure 7-4: Other Psychotherapeutic Drugs by Product Classification and Percent Distribution,
• Figure 7-5: Other Psychotherapeutic Drugs by Product Classification and Percent Market Share, 2005
• Figure 7-6: Other Psychotherapeutic Drugs by Product Classification and Percent Market Share, 2010
• Table 7-6: Other Psychotherapeutic Drug Market by Geographical Segment
• Figure 7-7: World Market:Other Psychotherapeutic Drug Market by Geographical Segment, 2003-2010
• Figure 7-8 Segment Percent Distribution, 2003-2010
• Figure 7-9: Market: Psychotherapeutic Drug Market by Geographical Segment and Percent Market Share, 2005
• Figure 7-10: World Market: Other Psychotherapeutic Drug Market by Geographical Segment and Percent Market Share, 2010
• Table 7-5: Estimated Other Psychotherapeutic Drug Sales by Indication, 2005 (in million of dollars at the manufacturers level)
• Figure 7-11: Estimated Other Psychotherapeutic Drug Sales by Indication, 2005
• Table 7-7: World Market Other Psychotherapeutic Drugs Leading Suppliers Shares by Market Revenues, Estimated 2005 and Projected 2010
• Figure 7-12: World Market Other Psychotherapeutic Drugs Leading Suppliers Market Share, Estimated 2005
• Figure 7-13: World Market Other Psychotherapeutic Drugs Leading Suppliers Market Share, Projected 2010
• Table 7-8: Psychotherapeutic Drug Market, 2003-2010 Top Drugs by Estimated Sales and Percent of Market, 2005 (in million of dollars at the manufacturers level)
• Figure 7-14: Other Psychotherapeutic Drug Market, 2003-2010 Top Drugs by Estimated Sales and Percent of Market, 2005

Chapter EIGHT: ISSUES AND TRENDS AFFECTING THE PSYCHOTHERAPEUTIC DRUG MARKET

• Table 8-1: Patent Data

Chapter NINE: THE EVOLVING PSYCHOTHERAPEUTIC DRUG MARKET

• Table 9-1: Psychotherapeutic Drug Market, 2003-2010
• Figure 9-1: Psychotherapeutic Drug Market, 2003-2010
• Figure 9-2: Psychotherapeutic Drug Market by Percent and Treatment Segment, 2005
• Figure 9-3: Psychotherapeutic Drug Market by Percent and Treatment Segment, 2010
• Table 9-2: Leading Suppliers, Products, and Segments of Participation 2005
• Figure 9-4: Leading Suppliers Market Shares 2005